Assessing the cost-effectiveness of switching from a β-blocker to latanoprost in the treatment of ocular hypertension

Author： Costagliola Ciro   Parmeggiani Francesco   Sebastiani Adolfo  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.4, Iss.10, 2003-10, pp. : 1775-1788

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost Effectiveness of Travoprost versus a Fixed Combination of Latanoprost/Timolol in Patients with Ocular Hypertension or Glaucoma: Analysis Based on the UK General Practitioner Research Database

By Renato De Natale  

Clinical Drug Investigation, Vol. 29, Iss. 2, 2009-01 ,pp. : 111-120

Adis International

Access to resources Recommend Favorite

Latanoprost: An Update of its Use in Glaucoma and Ocular Hypertension

By Perry C.M.   McGavin J.K.   Culy C.R.   Ibbotson T.  

Drugs & Aging, Vol. 20, Iss. 8, 2003-01 ,pp. : 597-630

Adis International

Access to resources Recommend Favorite

The cost-effectiveness of sertraline in the treatment of depression

By Olvey Eleanor L   Skrepnek Grant H  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 14, 2008-10 ,pp. : 2497-2508

Informa Healthcare

Access to resources Recommend Favorite

Assessment of the Cost Effectiveness of Travoprost versus Latanoprost as Single Agents for Treatment of Glaucoma in France

By Payet Stéphanie  

Clinical Drug Investigation, Vol. 28, Iss. 3, 2008-01 ,pp. : 183-198

Adis International

Access to resources Recommend Favorite

Cost-Effectiveness of Losartan Versus Atenolol in Treating Hypertension—An Analysis of the LIFE Study from a Swiss Perspective

By Szucs Thomas   Burnier Michel   Erne Paul  

Cardiovascular Drugs and Therapy, Vol. 18, Iss. 5, 2004-09 ,pp. : 391-397

Springer Publishing Company

Access to resources Recommend Favorite